
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 11, 2021

MEDAVAIL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

000-53298
(Commission File Number)

90-0772394
(I.R.S. Employer
Identification Number)

**6665 Millcreek Dr. Unit 1,
Mississauga ON Canada
L5N 5M4**
(Address of principal executive offices)

+1 (905) 812-0023
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	MDVL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On August 11, 2021, MedAvail Holdings, Inc. ("MedAvail" or the "Company") issued a press release to announce that SpotRx has been selected as a Partner Pharmacy of Zipdrug, now part of IngenioRx, Inc., a wholly owned subsidiary of Anthem, Inc. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information is intended to be furnished under Items 8.01 and 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statement and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	MedAvail Holdings, Inc. Press Release dated August 11, 2021

SpotRx Joins Zipdrug's Pharmacy Network

The partnership enables health plan members to be connected to SpotRx

MISSISSAUGA, Ontario and PHOENIX, Ariz. – August 11, 2021 – MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail"), a technology-enabled retail pharmacy company, today announced that SpotRx has been selected as a Partner Pharmacy of Zipdrug, now part of IngenioRx, Inc., a wholly owned subsidiary of Anthem, Inc.

Zipdrug's solution focuses on connecting consumers with mainly chronic conditions to high-performing independent pharmacies that have a proven track record of providing impactful clinical care with higher patient adherence rates, by delivering needed medications directly to a patient's home, ultimately improving patient outcomes. In the Tucson area, SpotRx will be serving as Zipdrug's only preferred pharmacy. IngenioRx members in the Tucson area utilizing retail pharmacies considered to be low performing by IngenioRx or out of network will have the option to be connected by Zipdrug to SpotRx and have SpotRx transfer their medications. SpotRx is also working with Zipdrug in southern California as one of several preferred pharmacies.

"We are honored to have been selected by Zipdrug, a data-driven company focused on simplifying the pharmacy experience and dynamically allocating Medicare Advantage patients nationwide to independent pharmacies driving better adherence," said Ed Kilroy, Chief Executive Officer at MedAvail. "Zipdrug's Pharmacy Network is currently available in a number of states, including California, Arizona, and Florida. In the Tucson area in which we currently operate, thousands of lives are covered by IngenioRx. We are looking forward to expanding our partnership with Zipdrug in the coming months."

"Our partnership with Zipdrug represents a significant milestone, underscoring our ability to meet important quality and performance thresholds to be selected as a Partner Pharmacy," said Neil Prezioso, Chief Pharmacy Officer. "We are excited about the opportunity to provide a convenient, quality experience through SpotRx to patients served by Zipdrug."

About SpotRx

SpotRx places control of the pharmacy experience back in the hands of consumers. SpotRx is a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery capability.

About MedAvail

MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes. Learn more at www.medavail.com.

Contacts:

Investor Relations

Caroline Paul
Gilmartin Group
ir@medavail.com

SOURCE MedAvail Holdings Inc.